Zhijie Li1, Fei Tan, David J Liewehr, Seth M Steinberg, Carol J Thiele. 1. Cell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, 10 Center Drive MSC-1928, Bldg 10/CRC 1-3940, Bethesda, MD 20892, USA.
Abstract
BACKGROUND: Activated AKT is a marker of decreased event-free or overall survival in neuroblastoma (NB) patients. The aim of this study was to investigate the effect of perifosine, a nontoxic AKT inhibitor, as a single agent on NB cell growth in vitro and in vivo. METHODS: Four human NB cell lines (AS, NGP, BE2, and KCNR) were treated with increasing concentrations of perifosine, and a quantitative analysis of cell death (apoptosis) was performed by using MTS and caspase-3/7 activity assays. Survival of mice carrying xenograft NB tumors that were treated with perifosine (n = 6-7 mice per group) was compared with that of untreated mice (n = 7 mice per group) using Kaplan-Meier analysis. Tumor volumes were calculated to determine the effect of perifosine on NB tumor growth. Phosphorylation of AKT and expression of cleaved caspase-3 were measured in proteins from the tumors. All statistical tests were two-sided. RESULTS: Perifosine, at 30 muM concentration, decreased AKT phosphorylation and increased apoptosis in all four NB cell lines in vitro. Perifosine-treated mice bearing xenograft NB tumors had longer survival than untreated mice (untreated vs treated, median survival: AS, 13 days, 95% confidence interval [CI] = 11 to 16 days vs not reached, P = .003; NGP, 22 days, 95% CI = 20 to 26 days vs not reached, P = .013; BE2, 24 days, 95% CI = 21 to 27 days vs not reached, P < .001; and KCNR, 18 days, 95% CI = 18 to 21 days vs not reached, P < .001). Perifosine treatment induced regression in AS tumors, growth inhibition in BE2 tumors, and slower growth in NGP and KCNR tumors. Inhibition of AKT phosphorylation and induction of caspase-dependent apoptosis were noted in tumors of perifosine-treated mice in all four in vivo NB tumor models. CONCLUSIONS: Perifosine inhibited the activation of AKT and was an effective cytotoxic agent in NB cells in vitro and in vivo. Our study supports the future clinical evaluation of perifosine for the treatment of NB tumors.
BACKGROUND: Activated AKT is a marker of decreased event-free or overall survival in neuroblastoma (NB) patients. The aim of this study was to investigate the effect of perifosine, a nontoxic AKT inhibitor, as a single agent on NB cell growth in vitro and in vivo. METHODS: Four human NB cell lines (AS, NGP, BE2, and KCNR) were treated with increasing concentrations of perifosine, and a quantitative analysis of cell death (apoptosis) was performed by using MTS and caspase-3/7 activity assays. Survival of mice carrying xenograft NB tumors that were treated with perifosine (n = 6-7 mice per group) was compared with that of untreated mice (n = 7 mice per group) using Kaplan-Meier analysis. Tumor volumes were calculated to determine the effect of perifosine on NB tumor growth. Phosphorylation of AKT and expression of cleaved caspase-3 were measured in proteins from the tumors. All statistical tests were two-sided. RESULTS:Perifosine, at 30 muM concentration, decreased AKT phosphorylation and increased apoptosis in all four NB cell lines in vitro. Perifosine-treated mice bearing xenograft NB tumors had longer survival than untreated mice (untreated vs treated, median survival: AS, 13 days, 95% confidence interval [CI] = 11 to 16 days vs not reached, P = .003; NGP, 22 days, 95% CI = 20 to 26 days vs not reached, P = .013; BE2, 24 days, 95% CI = 21 to 27 days vs not reached, P < .001; and KCNR, 18 days, 95% CI = 18 to 21 days vs not reached, P < .001). Perifosine treatment induced regression in AS tumors, growth inhibition in BE2 tumors, and slower growth in NGP and KCNR tumors. Inhibition of AKT phosphorylation and induction of caspase-dependent apoptosis were noted in tumors of perifosine-treated mice in all four in vivo NB tumor models. CONCLUSIONS:Perifosine inhibited the activation of AKT and was an effective cytotoxic agent in NB cells in vitro and in vivo. Our study supports the future clinical evaluation of perifosine for the treatment of NB tumors.
Authors: Girija P Dasmahapatra; Parijat Didolkar; Michael C Alley; Somiranjan Ghosh; Edward A Sausville; Krishnendu K Roy Journal: Clin Cancer Res Date: 2004-08-01 Impact factor: 12.531
Authors: Seon Young Nam; Hye Seung Lee; Gyung-Ah Jung; Jimi Choi; Sung Jin Cho; Min Kyu Kim; Woo Ho Kim; Byung Lan Lee Journal: APMIS Date: 2003-12 Impact factor: 3.205
Authors: Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Oren J Becher; Ellen M Basu; Stephen S Roberts; Kim Kramer; Ira J Dunkel Journal: Int J Cancer Date: 2016-09-30 Impact factor: 7.396
Authors: Marion Le Grand; Kathleen Kimpton; Christine C Gana; Emanuele Valli; Jamie I Fletcher; Maria Kavallaris Journal: ACS Pharmacol Transl Sci Date: 2020-01-23
Authors: Carolina H Thomé; Guilherme A dos Santos; Germano A Ferreira; Priscila S Scheucher; Clarice Izumi; Andreia M Leopoldino; Ana Maria Simão; Pietro Ciancaglini; Kleber T de Oliveira; Alice Chin; Samir M Hanash; Roberto P Falcão; Eduardo M Rego; Lewis J Greene; Vitor M Faça Journal: Mol Cell Proteomics Date: 2012-09-22 Impact factor: 5.911
Authors: Roberta Marino; Dana C Baiu; Saswati Bhattacharya; Benjamin Titz; Ellen Hebron; Bryan D Menapace; Sorabh Singhal; Jens C Eickhoff; Fotis Asimakopoulos; Jamey P Weichert; Mario Otto Journal: Am J Cancer Res Date: 2015-10-15 Impact factor: 6.166